Search

Parathyroid hormone

Food and Drug Administration (FDA). … Available as Preotact, it is an identical form of human recombinant hormome which produced as a fusion protein undergoeing post-translational processing involving the cleavage of the OmpA leader sequence

Clenoliximab

Clenoliximab is a chimeric monoclonal antibody from _Macaca irus_ against CD4 which acts as an immunomodulator. It has investigated for the treatment of rheumatoid arthritis.

Orforglipron

[L56123] On April 1, 2026, the US FDA granted approval to orforglipron for use alongside diet and exercise to aid in weight reduction in certain patient populations.

Lonoctocog alfa

Amyl Nitrite

As an inhalant, it also has psychoactive effect which has led to illegal drug use. … Amyl Nitrite is an antihypertensive medicine. Amyl nitrite is employed medically to treat heart diseases such as angina and to treat cyanide poisoning.

Corticorelin ovine triflutate

If corticorelin injection results in an increase of plasma ACTH and cortisol, the patient is diagnosed with Cushing's disease. … However, if corticorelin injection does not result in an increase of plasma ACTH and cortisol, the patient is diagnosed with ectopic ACTH syndrome.

Fosdenopterin

In 2009 a recombinant, E. coli-produced cPMP was granted orphan drug designation by the FDA, becoming the first therapeutic option for patients with MoCD type A. … Molybdenum cofactor deficiency (MoCD) is an exceptionally rare autosomal recessive disorder resulting in a deficiency of three molybdenum-dependent enzymes: sulfite oxidase (SOX), xanthine dehydrogenase

PRO 2000

PRO 2000 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials.

Triflusal

Uriach and Company and even though it is commercialized in different countries it is not approved by the FDA, EMA or HealthCanada. … Triflusal is a 2-acetoxy-4-trifluoromethylbenzoic acid and it is an aspirin chemically-related molecule but not a derivative.

Alfuzosin

[L31593] It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies.[L9251] … [A228483] Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works by relaxing the muscles in the prostate and bladder neck.